Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
AUSTIN, Texas, Jan. 17, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced the publication of results from its pivotal phase 3 trial of the Company’s lead monoclonal antibody...
-
AUSTIN, Texas, Dec. 07, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, today announced that enrollment has been completed in its randomized,...
-
AUSTIN, Texas, Dec. 06, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, today announced that enrollment has been completed in its randomized,...
-
XBiotech's True Human antibodies Targeting IL-1 alpha (IL-1alpha) to be used in Researching Treatment for Inflammatory Bowel Disease (IBD) AUSTIN, Texas, Nov. 17, 2016 (GLOBE NEWSWIRE) --...
-
AUSTIN, Texas, Nov. 10, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, announced today that it will host a live conference call and webcast...
-
AUSTIN, Texas, Oct. 12, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ therapeutic antibodies, today announced a successful GMP (Good Manufacturing...
-
AUSTIN, Texas, Oct. 11, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ therapeutic antibodies, today announced that the U.S. District Court for the...
-
AUSTIN, Texas, Aug. 22, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ therapeutic antibodies, today announced the timing for the grand opening of...
-
AUSTIN, Texas, Aug. 10, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, announced today that it will host a live conference call and webcast...
-
AUSTIN, Texas, July 22, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ antibody therapies, said today that the Independent Data Monitoring Committee...